Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

1. The pathogenesis of sepsis.Annual review of pathology · 2011
   Review
2. Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants.The Journal of thoracic and cardiovascular surgery · 2010
   Article
3. Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue.PloS one · 2010
   Article
4. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery.The Annals of thoracic surgery · 2010
   Article

Corrections and comments

• Comment on
  Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?2009

Authors and funding

5 authors at 5 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as